Teleflex Raises 2026 Earnings Guidance
The medical technology company lifted its full-year adjusted earnings forecast after a 39% rise in third-quarter adjusted profit.
Updated on Nov. 17, 2026 in Corporate Finance

Teleflex raised its 2026 full-year adjusted earnings guidance to $7.50 to $7.75 per share after reporting third-quarter results. The company completed the $1.5 billion cash sale of its original equipment manufacturer business to Montagu and Kohlberg in August.
Why it matters
The update reflects improved profitability alongside tariff refunds and a portfolio restructuring aimed at concentrating operations on selected medical technology markets. Teleflex also repurchased about $350 million of its common stock since July 1, redirecting capital toward shareholders and remaining operations.
Third-quarter revenue from continuing operations totaled $567.8 million, while adjusted diluted earnings rose to $2.63 per share from $1.89 a year earlier. The company has repurchased $600 million in shares during 2026, with $400 million remaining under its authorization as of Nov. 5.
The players
Teleflex Incorporated
A medical technology company headquartered in Wayne, Pennsylvania, that is restructuring its operations into three global, product-based segments.
Montagu and Kohlberg
Private equity firms that acquired Teleflex's original equipment manufacturer business in a $1.5 billion cash transaction completed in August.
Sean M. Salmon
A director added to Teleflex's board of directors in September as the company continues its governance and strategic changes.
The details
Teleflex received $39.2 million in tariff refunds during the quarter tied to tariffs invalidated by a February 2026 U.S. Supreme Court decision. The company used part of the original equipment manufacturer sale proceeds to repay a $700 million term loan and reduce revolving credit borrowings.
Timeline
February 2026: U.S. Supreme Court invalidated IEEPA tariffs.
December 2025: Board approved a $1 billion share repurchase authorization.
July 1, 2026: Recent share repurchase period began.
August 2026: Completed the $1.5 billion OEM business sale.
September 30, 2026: Third-quarter reporting period ended.
Market Dynamics
The earnings gain depends partly on refunds from tariffs struck down by the U.S. Supreme Court in February 2026, a one-time benefit layered on top of Teleflex's ongoing portfolio simplification. Its pivot toward three product-based segments mirrors a broader corporate pattern of shedding non-core units to focus capital on remaining medical technology operations.
Shareholders benefit from the buyback program, which has retired $600 million in shares in 2026 at an average price of $128.96 since July 1. Investors should watch whether the updated $7.50 to $7.75 guidance holds once the pending divestitures close and proceeds are applied to debt and share purchases.
The takeaway
Companies that simplify their portfolios and return capital through buybacks can lift per-share earnings even when headline revenue is flat. Investors should separate one-time items like tariff refunds from recurring operating improvements when judging a company's guidance.
What happens next
Teleflex expects to complete the Acute Care and Interventional Urology sale by the end of 2026, though the transaction could extend into 2027.
Further reading
For broader context on how divestitures and buybacks shape company valuations, explore Corporate Finance coverage.
Source note: This article includes information reported by MyChesCo.






